Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 3/20 | 0.41 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29807425 | 1.00 | TDP2 (0.45) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL936485 | 0.88 | MAOA (0.48) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL8327818 | 0.88 | GRM5 (0.44) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL22579802 | 0.84 | TDP1 (0.42) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL31298937 | 0.81 | GRM5 (0.40) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL5235719 | 0.77 | TDP2 (0.37) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL9282891 | 0.75 | TDP2 (0.42) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL6385750 | 0.75 | CES1 (0.59) | CES1KMT2ATDP1GAAPTPRC | |
| SCHEMBL13845088 | 0.74 | CYP19A1 (0.36) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL19453621 | 0.74 | TDP1 (0.40) | TDP2NSD2ABL1PLCG1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850172-A | Method for preparing 6,7-dihydrocyclopenta [ b ] pyridine-5-ketone by catalytic oxidation | 沈阳化工研究院有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-110577493-A | Preparation method of 6, 7-dihydro-5H-cyclopenta [ b ] pyridine-5-ketone | 南京格亚医药科技有限公司 | 2019-12-17 | — | — | CN | claimed |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT | 2024-11-14 | — | — | US | disclosed |
| WO-2024220641-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 USEFUL FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240270759-A1 | Preparation of SHP2 phosphatase inhibitors and its applications | YA THERAPEUTICS INC (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-118265700-A | Substituted naphthyridinone derivative, pharmaceutical composition and application thereof | 上海海雁医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-115960109-B | Preparation and application of condensed ring SHP2 phosphatase inhibitor | 药雅科技(上海)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-12006323-B2 | Ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-118061603-A | Wear-resistant recyclable honeycomb structure box and preparation method thereof | 蜂井包装工业无锡有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| EP-0028485-A1 | Spiro-imidazolones for alleviating diabetes-associated conditions, processes for preparing them, and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376114-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, XPO5, XPOT | TDP2 2888/4885NSD2 4024/4885ABL1 3950/4885 |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | TDP2 2695/4885NSD2 1325/4885ABL1 45/4885 |
| US-20240270759-A1 | Preparation of SHP2 phosphatase inhibitors and its applications | PTPN2, PTPN22, PTPN5 | TDP2 2709/4885NSD2 1198/4885ABL1 43/4885 |
| US-12006323-B2 | Ethynyl derivatives | GRM4, GRM2, GRIA4 | TDP2 2087/4885NSD2 1145/4885ABL1 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.